Post-approval studies (Phase 4)Study completedNCT04792567
What this trial is testing
Exploring the Immune Response to SARS-CoV-2 modRNA Vaccines in Patients With Secondary Progressive Multiple Sclerosis (AMA-VACC)
Who this might be right for
Secondary Progressive Multiple Sclerosis
Novartis Pharmaceuticals 41